FDA Warns CBD Companies for Making Unauthorized Health Claims
The FDA continues to crack down on CBD companies promoting unauthorized products.
Just last week, it issued letters of warning to BIOTA and Homero Corp for selling and marketing CBD products which were in direct violation of the Federal Food, Drug, and Cosmetic Act.
One of the main issues the FDA warns against is the promotion of CBD products as a proven treatment for various medical conditions, one being opioid addiction.
The Seattle-based BIOTA markets and distributes injectable CBD products, including injectable curcumin products, which the company claims can be used to treat serious health conditions, such as epilepsy and neuropathy conditions.
Homero also markets and sells cannabidiol products as an effective treatment for opioid addiction and other serious illnesses. This New Hampshire-based firm distributes its own label of CBD products.
The companies have 15 business days to respond. Otherwise, they could face legal action, including seizure and injunction.
Although there have been studies exploring the link between cannabis and opioid addiction, there is still no conclusive proof that CBD is a safer and more effective alternative.
It is a serious problem in the US and people dealing with opioid addiction require authorized treatment from a healthcare provider, the FDA concluded.
The Agency has also expressed concern over the quality of CBD products, noting that the production process of cannabidiol drugs is not subject to FDA review. They added that there are still many questions to be answered regarding the usefulness and safety of CBD products, such as dosing, interaction with other drugs and possible side-effects.
So far, the FDA has sent warning letters to other CBD companies promoting cannabidiol products as safe and effective treatment for the prevention of COVID-19.
According to FDA Commissioner Stephen M. Hahn, M.D., the sale and marketing of CBD as an effective cure against the novel coronavirus is a threat to public health — hence why the Agency will “aggressively pursue” companies looking to cash in by making fraudulent claims during times of crisis.